News >

Maintenance Pembrolizumab Extends PFS in Metastatic Urothelial Cancer

Ellie Leick
Published: Thursday, Jun 27, 2019

Matthew Galsky, MD

Matthew Galsky, MD
Switch maintenance treatment with pembrolizumab (Keytruda) improved progression-free survival (PFS) in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy, according to results of a randomized phase II study that were presented at the 2019 ASCO Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication